| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6830546 | Seizure | 2016 | 24 Pages |
Abstract
Although the overall risk of MS was similar in patients with epilepsy who were treated with VPA or CBZ, the distribution of MS components differed between treatment groups. Patients treated with CBZ or VPA less frequently had decreased high-density lipoprotein cholesterol levels or increased blood glucose concentrations, respectively. Females on VPA treatment could be at higher risk of MS than males.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Aleksei Rakitin, Sulev Kõks, Sulev Haldre,